Korro Bio, INC Form 4 insider transactions

Jean Francois Formela, a Director of Korro Bio, Inc., sold 2,143 shares of common stock on August 11, 2026 for $13.96 per share.

Lynx1 Capital Management LP and 1 other reported changes in beneficial ownership of Korro Bio, Inc. common stock on August 6, 2026.

Loic A Vincent, Chief Scientific Officer of Korro Bio, Inc., received 7,500 shares of common stock on July 15, 2026.

Oliver Dolan, Senior Vice President, Finance of Korro Bio, Inc., received 5,500 shares of common stock on July 15, 2026.

Jeffrey Cerio, General Counsel of Korro Bio, Inc., received 6,500 shares of common stock on July 15, 2026.

Todd Chappell, Chief Operating Officer of Korro Bio, Inc., received 7,500 shares of common stock on July 15, 2026.

Korro Bio, Inc. director Jean Francois Formela reported the sale of common stock totaling 85,955 shares under a pre-established Rule 10b5-1 trading plan.

Korro Bio, Inc. Director Jean Francois Formela reported the sale of common stock totaling over 160,000 shares across multiple transactions executed between June 22 and June 24, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Korro Bio's Chief Operating Officer, Todd Chappell, reported a transaction involving the sale of 3,168 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

Korro Bio Chief Scientific Officer Vincent Loic A reports a mandatory sale of 3,418 common shares to cover tax obligations from a restricted stock unit vesting.

Korro Bio's General Counsel, Jeffrey Cerio, reported a transaction involving the sale of 6,609 shares of common stock to cover tax obligations related to restricted stock units.

Korro Bio, Inc. reports a Form 4 filing detailing a transaction by Senior Vice President of Finance, Oliver Dolan, involving the sale of common stock to cover tax obligations.

Director Ali Behbahani was granted 14,677 stock options in Korro Bio, Inc. as part of standard director compensation.

Director Rachel Meyers was granted 14,677 stock options in Korro Bio, Inc. as part of a standard equity compensation arrangement.

Director Nessan Bermingham was granted 14,677 stock options in Korro Bio, Inc. as part of a standard equity compensation package.

Director Katharine Knobil was granted 14,677 stock options in Korro Bio, Inc. as part of standard equity compensation.

Director Jean-Francois Formela was granted 14,677 stock options in Korro Bio, Inc. as part of standard director compensation.

Director Timothy R. Pearson was granted 14,677 stock options in Korro Bio, Inc. as part of standard compensation.

Korro Bio President and CEO Ram Aiyar reported a sale of 15,152 shares of common stock to cover tax obligations related to a performance stock unit settlement.

Director Jean-Francois Formela sold 2,860 shares of Korro Bio, Inc. common stock via a pre-arranged 10b5-1 trading plan.

Korro Bio President and CEO Ram Aiyar acquired 50,000 shares of common stock following the vesting of performance stock units.

Lynx1 Capital Management LP acquired 520 additional shares of Korro Bio, Inc. at a price of $10.60 per share.

Korro Bio's Director and 10% owner, Rick Yang, indirectly acquired over 440,000 shares and warrants through a private placement.

Korro Bio Director Scott D. Sandell, through New Enterprise Associates 17, L.P., acquired additional common stock and pre-funded warrants from the issuer.

New Enterprise Associates 17, L.P. increased its beneficial ownership in Korro Bio, Inc. through the acquisition of common stock and pre-funded warrants.

Korro Bio, Inc. Director and 10% owner Carmen Chang, through affiliated entities, acquired 207,100 shares of common stock and 242,945 pre-funded warrants for a total investment exceeding $4.9 million.

Korro Bio Director and 10% owner Ali Behbahani, through New Enterprise Associates 17, L.P., acquired 207,100 shares of common stock and 242,945 pre-funded warrants from the issuer on March 10, 2026.

Forest Baskett, a director and 10% owner of Korro Bio, Inc., acquired over 440,000 shares and pre-funded warrants in a recent transaction.

Korro Bio Director Edward T Mathers, through affiliated entities, acquired over 450,000 shares and warrants in the company for approximately $5 million.

Mohamad Makhzoumi, a Director and 10% owner of Korro Bio, Inc., indirectly acquired common stock and pre-funded warrants totaling approximately $5.0 million from the issuer.